Vantage logo

Reality bites for Macrogenics 

Hopes are fading for margetuximab in breast cancer, which looks unlikely to show an overall survival benefit in the Sophia study. 

Vantage logo

Immunogen fails to leap Forward

As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.